15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis | Zendy

Rainer Birck | Zendy; Mark Newman | Zendy; Claude Braun | Zendy; Irmgard Neumann | Zendy; Kyuichi Nemoto | Zendy; Benito A. Yard | Zendy; Rüdiger Waldherr | Zendy; Fokko J. van der Woude | Zendy

Open Access

15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis

Author(s) -

Rainer Birck,

Mark Newman,

Claude Braun,

Irmgard Neumann,

Kyuichi Nemoto,

Benito A. Yard,

Rüdiger Waldherr,

Fokko J. van der Woude

Publication year - 2005

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfi070

Subject(s) - medicine , cyclophosphamide , proteinuria , mycophenolate , gastroenterology , nephritis , blood urea nitrogen , urology , kidney , transplantation , chemotherapy

Here we compare the efficacy of cyclophosphamide (CYC) for treatment of crescentic nephritis (CGN) with the newer immunosuppressants 15-deoxyspergualin (DSG) and mycophenolate mofetil (MMF) in SCG/Kj mice, an inbred mouse strain that spontaneously develops CGN, systemic necrotizing vasculitis and antineutrophil cytoplasmic antibodies (ANCAs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research